Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
Keith C HayesDepartment of Physical Medicine and Rehabilitation, The University of Western Ontario, London, ON, CanadaAbstract: Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K+) channel-blocking compounded dalfampridine, also known as fampridine, and chemically&a...
Guardado en:
Autor principal: | |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ca611cb145b34bab91b18fb7e442dcf5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|